FULL EVENT GUIDE

Browse the Event Guide for Exclusive Insights from the Likes Of:

Aarti Sharma

Associate Director

Regeneron Pharmaceuticals Inc

Arti Patel

Principle Scientist II

Novartis AG

Mansuo Lu Shannon

Chief Scientific Officer

Prevail Therapeutics

Bijan Nejadnik

Head of Global Development, Regulatory Affairs & Quality Assurance

Mitsubishi Tanabe Pharma

Neta Zach

Head of Neuroscience Experimental Medicine

Takeda Pharmaceutical Co. Ltd.

Petra Duda

Head of Development

UCB Pharma

DOWNLOAD HERE

3-Day Full Agenda Including:

40+

industry leading speakers from the likes of Biogen, Novartis, Sanofi, Takeda, UCB, Denali and AbbVie 

6

hours of intimate pre-conference workshop discussions, delving into TDP-43 based biomarkers, combination therapy and novel surrogate endpoints advancing beyond ALSFRS-R

8+

hours of dedicated networking time across speed networking, roundtable discussions, panels and more 

1

scientific poster session, giving you the opportunity to display your own research to this diverse audience of discovery, preclinical and clinical ALS experts

ALS Drug Development Summit

Having trouble downloading the brochure?
Let us know and we’ll email it to you instead

“I am especially eager for the sessions on emerging therapeutic targets, pioneering drug modalities, and inventive clinical trial designs. Furthermore, sessions that shed light on patient perspectives will be invaluable in understanding the unmet needs.”

Shiran Zimri, Vice President, R&D, NeuroSense

“Most looking forward to sessions on navigating the complexity of causative genes and risk factors for ALS to give rise to next-generation targets.”

Sophie Parmentier-Batteur, Head of Neurodegeneration, Novartis

“Looking forward to discussion around new biomarkers, that could aid in earlier ALS diagnosis and increase our ability to predict disease progression.”

Stacy Lindborg, Co-Chief Executive Officer, BrainStorm Cell Therapeutics

 

Companies On The Program:

Companies on the program
REGISTER YOUR PASS
BACK TO TOP